Article Details

Roche Withdraws Application for Atezolizumab in Early or Locally Advanced TNBC in Europe

Retrieved on: 2021-07-26 20:10:03

Tags for this article:

Click the tags to see associated articles and topics

Roche Withdraws Application for Atezolizumab in Early or Locally Advanced TNBC in Europe. View article details on hiswai:

Excerpt

Roche Registration GmbH has withdrawn its application to extend the use of atezolizumab (Tecentriq) to the treatment of patients with early or locally ...

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up